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The biological  properties of a  human adenovims that has incorporated defective 
SV40 genetic material within its adenocapsid have been extensively studied  (1, 2). 
The particle containing the defective SV40 genome is known as PARA (2). Its presence 
confers new properties on the adenovirus population  which now replicates in simian 
cells (3), carries the genetic information for the synthesis of SV40 tumor (T) antigen 
(4,  5)  and SV40 specific transplantation antigens  (6),  and is oncogenic  in newborn 
hamsters (1, 7). 
Genetic material from PARA can be transferred to other human adenovimses by 
a process called  transcapsidation (8, 9). As a  result of such transfer to type 2,  this 
previously nononcogenic  adenovirus produced  tumors when  injected  into  newborn 
hamsters (7,  10). These tumors were characteristic of either SV40-induced  tumors, 
adenovirus-like  tumors,  or  contained  elements  of  both  types.  Hamster  cells 
transformed in vitro by PARA-adenovirus 2 yielded similar tumors when inoculated 
into weanling  hamsters (11). 
The  PARA  component  has  also  been  transferred  to  seven  other  human 
adenovirus serotypes. The in vitro properties of these  newly created popula- 
tions have been reported (12). To determine whether the acquisition of defec- 
tive SV40 conferred oncogenic potential to all adenoviruses, these populations 
were  tested  by injecting  them  into  newborn  hamsters.  The  ability  of  these 
viruses to protect hamsters against challenge with cells transformed by SV40 
virus was also investigated. The results of these studies,  which indicate  that 
the  acquisition  of  the  SV40  genome  does  not  necessarily  confer  oncogenic 
potential to an adenovirus, are presented in this paper. 
Materials and Metkods 
Viruses.--The history of the PARA-adenovirus type 7 (stock SP2) used in this study has 
been described in detail  (6). The virus was passed two additional times in primary African 
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green monkey kidney (GMK) cells.  Adenovirus type 2 was a  local strain. Adenovirus types 
1, 5, 6, 14, and 16 were the prototype virus strains obtained from the National Communicable 
Disease  Center,  Atlanta,  Ga.  Adenovirus type 21  was  obtained from  the Amercian Type 
Culture Collection, Rockville, Md. These adenoviruses were passed twice in KB cells and once 
in primary human embryonic kidney  (HEK)  cells in our laboratory. The HEK  cells were 
supplied by the Human Tissue Procurement Program, National Cancer Institute, Bethesda, 
Md. Adenovirus type 3 had been obtained from Wyeth Laboratories (Philadelphia, Pa.) and 
had been passed four times in KB cells,  plaque-purified twice in HEK cells, and then passed 
once in the same cells.  None of these viruses carried genetic information needed to induce 
known SV40 antigens and none could replicate well in simian cells in the absence of SV40 or 
PARA (12). 
The process of transferring the PARA component to these human adenovirus populations 
has been described (8, 12). Terminal dilutions of PARA-adenovirus 7 were plated onto GMK 
cells growing in 60 X  15 mm plastic Petri dishes. The cells were simultaneously inoculated 
with a saturating amount of the human adenovirus which alone caused no plaques in the simian 
cells.  The  plaques  that  were  produced  in  doubly  infected  cells  were  picked  and  tested 
for traascapsidants. Residual adenovirus type 7 was neutralized by exposing the virus from 
the plaque to type-specific adenovirus 7 antiserum for 1 hr at 37°C. Stocks were then prepared 
by inoculating the virus onto GMK cells growing as monolayers in 16 oz prescription bottles. 
The cultures were harvested when cytopathic effects were maximal by two cycles of quick- 
freezing in an alcohol-dry ice bath followed by thawing at 37°C. The cell debris was removed 
by low speed centrlfugation and the supernatant used as virus stock. 
SV40 was the Baylor reference strain used in previous studies reported from this laboratory 
(13,  14). 
Virus A ssays.--Since PARA-adenovirus populations are made up of two kinds of particles, 
a  true  adenovirion  and  an  adenovirus  capsid  containing  defective  SV40  genetic  mate- 
rial (PARA), titrations for each component were carried out separately. The human adeno- 
virus component was titrated in HEK cells by the plaque technique (15). The HEK cells were 
grown in 35 X  10 mm plastic Petri dishes in Melnick's lactalbumin hydrolysate medium (M-E) 
with 10% fetal calf serum and 0.23% NaHCO3.  All media contained 100 units of penicillin 
and 100/zg of streptomycin per milliliter. 10-fold  dilutions of the virus were plated in 0.1 ml 
amounts onto replicate cultures, and the virus was allowed to adsorb for 1 hr at 37°C with 
frequent manual rotation of the plates. Then, 1.5 ml of overlay containing 1% agar, 10% fetal 
calf serum, and 0.23% NaHCO3 in Eagle's medium was added. A second overlay with neutral 
red was added 1 wk later, and plaques were counted on the 10th day after inoculation. 
For  titration  of  PARA,  GMK  cells  were  grown  in  60  X  15  mm  plastic  Petri 
dishes in Melnick's lactalburnin hydrolysate (M-H) with 2% calf serum and 0.08% NaItCO3. 
10-fold dilutions in 0.1 ml amounts were plated onto the GMK cells in the presence of a satu- 
rating amount of nonreplicating helper human adenovirus (16). After adsorption of the virus 
for 1 hr at 37°C, 5 ml of an overlay similar to the one described above were added. A second 
overlay with neutral red was added  1 wk later; the plaques were counted 10-12 days after 
inoculation of the virus. 
Immunofluorescence Techni,  clues.--Cells were grown on 15 mm round cover slips. The cells 
were washed three times with warm Tris buffer (pH 7.4), air dried, and fixed in acetone for 3 
rain. They then were reacted with antisera for 30 rain, washed 3 times with Tris buffer, and 
reacted with fluorescein-labeled antiglobulin for 30 rain. After three washings with Tris buffer 
followed  by  drying  at  room  temperature,  the  cover  slips  were  mounted  in  Elvanol 
and examined with a  Zeiss fuorescence microscope. The details of the preparations of the 
reagents and the procedures employed have been described (14,  17). 
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ing the serum with GMK cells inoculated 24 hr previously with SV40.  Fluorescein-labeled 
anti-hamster globulin was then added. The same sera were tested for the presence of anti- 
bodies against adenovirus T  antigen by reacting the serum with HEK cells inoculated 24 hr 
earlier with the adenoviruses. Tumor cells were tested for the presence of SV40 T  antigen by 
reacting the cells with sera of hamsters bearing tumors induced by the inoculation of SV40- 
transformed, but virus-free (18), hamster cells (H-50 cell line). The cells were tested for SV40 
virus (V) antigen by reacting them with fluorescein-labeled anti-SV40 monkey serum. Adeno- 
virus T antigen was detected by reacting tumor cells with serum from hamsters bearing tumors 
induced by adenovirus type 12. The presence of adenovirus V antigen in the tumor cells was 
detected with type-specific anti-adenovirus 7 rabbit serum. 
Anima~ Experiments.--Newbom  hamsters were inoculated subcutaneously within 24 hr 
of birth with 0.1 ml of medium containing a PARA-adenovirus or a human adenovirus. The 
animals were weaned  3 wk after birth and  checked weekly for  tumor  development. When 
the tumors measured greater than 10 X  l0 ram, the animals were bled out and the sera col- 
lected. 
Some of the tumors were removed, trypsinized, and the cells grown in 16 oz prescription 
bottles in Eagle's medium with 10% fetal calf serum. The cells were tested for the presence 
of virus-specific antigens by immunofluorescence techniques. The tumor cells were also plated 
onto GMK and HEK cells in attempts to isolate virus. One blind passage of cell cultures not 
showing cytopathic effects was carried out. Tumor cell extracts (20%), prepared by two alter- 
nate cycles of qniek-freezing cells from the tumor in an alcohol-dry ice bath followed by thaw- 
ing at 37°C, were also examined for the presence of virus particles with the electron micro° 
scope. 
Transplantation rejection experiments were carried out by inoculating weanling hamsters 
three times at weekly intervals with various viruses followed by challenge with  cells trans- 
formed by SV40 (H-50 cell line). The dose of the immunizing viruses was adjusted  so that 
each hamster was inoculated with the same amount of adenovirus in the corresponding PARA- 
adenovirus population. Even though the amount of the  adenovirus was therefore constant 
for each serotype, these dilutions resulted in differing inocula of PARA serotypes per animal. 
The actual titers of both PARA and adenovirus inoculated are given in Table V. 
The H-50 cells, derived originally from a hamster tumor induced by  SV40 (19), had been 
passed about  100 times in tissue culture and were then  transplanted serially two times in 
hamsters to increase their transplantability. They were reestablished in tissue  culture and 
subsequently passed  10 times. The cells are free of infectious SV40  (18)  but  contain SV40 
intranuclear T  antigen  (20)  and surface  (S)  antigen demonstrable by immunofluorescenco 
(21). The challenge H-50 cells were inoculated subcutaneously using 10-fold dilutions ranging 
from 100 to 100,000 cells per animal. Eight animals were used for each concentration of cells; 
i.e., 32 animals were employed for each virus. The number of cells required to produce tumors 
in 50% of the recipient animals (TPDs0) in each group was calculated by the method of Reed 
and Muench. 
RESULTS 
Oncogenicity of PARA-Adenovirus  Populations.~The various PARA-adeno- 
virus populations and the parent serotypes were injected subcutaneously into 
groups of new born hamsters within 24 hr after birth. The transfer of PARA 
to adenovirus types 3, 14, 16, and 21 failed to enhance the oncogenic potential 
of these viruses  (Table I).  Only one animal  in  this  group  (inoculated with 
PARA-adenovirus 3)  developed a  tumor  within  the  9  months  observation 
period. None of the animals inoculated with the parent serotypes  (i.e., before 80  ODENOVIRUSES  WITH  DEFECTIVE  SV40  GENOME 
the transfer of the PARA genome) developed a detectable neoplasm during this 
time. This is in contrast to animals inoculated with  the original PARA-adeno- 
virus  7  which  induced  tumors  in  49 %  of the  animals  inoculated  (Table  I). 
Some of the groups were inoculated in conjunction with experiments reported 
here, but the large number of animals cited in Table I  represent accumulated 
totals, some of which have been used  in a  previous report (7).  These viruses 
TABLE I 
Oncogenidty of Human  Adenoviruses with DNA  of Intermediate GC Content Before and 
After the Acquisition of Defective SV40 (PARA) 
Virus inoculated 
Adenovirus 3 
PARA-adeno 3 
Adenovirus 7 
PARA-adeno 7  [I 
Adenovirus 14 
PARA-adeno 14 
Adenovirus 16 
PARA-adeno 16 
Adenovirus 21 
PARA-adeno 21 
Plaque-formingunits 
inoculated 
'ARA  ~  Adenovims~ 
lOO.O 
103.1  106.0 
105.o_10  ~.o 
105.o  105.7-10  e.6 
10 6.2 
108.o  105.5 
100.5 
1~.8  10o.4 
105.1 
lOa.a  10~.2 
Hamster results 
Io.  ' Per cent 
~o.  ith  with 
w  aned  tl  ~ors  tumors§ 
12  0  0 
20  1  5 
17  0  0 
97  7  49 
12  0  0 
10  0  0 
9  0  0 
14  0  0 
20  0  0 
19  0  0 
Latent 
period 
wk 
19 
17-27 
* Obtained by plaque assay in green monkey kidney cells coinfected with a helper adeno- 
virus. 
:~ Obtained by plaque assay in human embryonic kidney cells. 
§ Based on number weaned. 
[[ From reference 7. 
are  all members of hemagglutinating  group I  (,22) with  demonstrated  onco- 
genesis (23)  and an intermediate (50-53 %) composition of guanine plus cyto- 
sine (GC) in the viral DNA (24). 
Similarly, newborn animals were inoculated with PARA-adenovirus or the 
parent serotypes belonging to hemagglutination  group 2  (22).  These viruses, 
including adenovirus types 1, 2, 5, and 6, have thus far been nononcogenic in 
newborn hamsters and contain DNA with a  high (56-58 %) GC content  (24). 
None of the parent serotypes produced tumors in the hamsters within the ob- 
servation period (Table II). However, all viruses of this group carrying PARA RAPP~ JERKOFSKY~ MELNICK~ AND LEVY  81 
became oncogenic. PARA-adenovirus 1 induced tumors in 35 % of the animals 
weaned; it took from 22 to 29 wk for these tumors to become palpable. A simi- 
lar  percentage  of  animals  inoculated  with  PARA-adenovirus  6  developed 
tumors. PARA-adenovirus 2 induced tumors in  19% of the animals weaned. 
Although only 3  of 51  animals  (6%)  developed tumors  after  inoculation of 
PARA-adenovirus 5,  these  tumors  all  developed very rapidly with  a  latent 
period of only 8-10 wk. 
Virologic  and Serologic Analysis  of Tumors and Hamster Sera.--It  had been 
TABLE II 
Oncogenicity of Human Adenoviruses with DNA of High GC Content Before and After the 
Acquisition  of Defective $40 (  P A RA ) 
Virus inoculated 
Adenovirus 1 
PARA-adeno 1 
Adenovirus 2 
PARA-adeno 2 
Adenovims 5 
PARA-adeno 5 
Adenovirus 6 
PARA-adeno 6 
Plaque-formlng units 
inoculated 
?ARA*  Adenovirus$ 
I 
--  l0  s.~ 
10  2. 8  10  O. S 
__  10 s.o 
104.o_  106-5_107.o 
105.o 
_  105. 6 
105.3  106.0 
__  105. s 
102.4  10  5. s 
NO, 
nocn- 
lated 
82 
81 
140 
340 
107 
110 
84 
81 
Hams~rr~ul~ 
No. 
weaned 
19 
40 
35 
128 
40 
51 
45 
44 
NO. 
with 
tBmors 
0 
14 
0 
24 
0 
14 
Per cent 
with 
tumors§ 
0 
35 
0 
19 
0 
32 
Latent 
pe~od 
wk 
22-29 
12-34 
8-10 
113-31 
* Obtained by plaque assay in green monkey kidney cells coinfected with a helper adeno- 
virus. 
:~ Obtained by plaque assay in human embryonic  kidney cells. 
§ Based on number weaned. 
previously  established  that  the  tumors induced  by PARA-adenovirus 2  (7, 
25)  and PARA-adenovirus 7 (1, 7) were virus-free.  Extracts prepared from 
tumors induced by  PARA-adenovirus types  1 and  6  failed  to  yield  recog- 
nizable virus particles when examined  in the electron microscope. A  total of 
14 (of 19 attempted)  of these tumors were trypsinized and established in cell 
culture.  Attempts to isolate either  SV40  or adenoviruses from these cultures 
by a  variety of techniques failed.  These  attempts  included  (a)  disruption of 
the tumor cells followed by plating on GMK and HEK cells  and,  (b) mixing 
the tumor cells with GMK and HEK cells and growing them together. 
Tumors were characterized histopathologically as previously described  (10) 82  ADENOVIRUSES  WITH  DEFECTIVE  SV40  G~--NOME 
and analyzed for virus T  antigens. The results with tumors induced by PARA- 
adenovirus types 2 and 7 have already been described (7,  10).  As with tumors 
induced by PARA-adenovirus 2 and PARA-adenovirus 7, most (5 of 6) of the 
PARA-adenovirus 1 tumors examined were found to synthesize SV40 T  anti- 
gen  (Table III). Correspondingly,  10  of  13  of the  hamster sera  examined in 
this group contained antibody against SV40 T  antigen. The number of tumors 
synthesizing detectable levels of adenovirus T  antigen was lower (2 of 6 exam- 
TABLE III 
Immunofluorescence  Analysis of PA RA-A denovirus 
Type of tumor  No. 
~denovirus  5 
N40  3 
Mixed  4 
~_typical  1 
Total ......  13 
Tumor Cells and Hamster  Sera 
Cells  Serum 
No. 
examined 
SV40 T 
antigen 
Adeno T 
iLntigen 
No. 
examined 
SV40 T 
antibody 
Adeno T 
antibody 
6  5  2  13  10  7 
TABLE IV 
lmmunofluorescence  Analysis of PARA-Adenovirus  Tumor Cells and Hamster  Sera 
Cells  Serum 
Type of  tumor  No. 
No.  SV40 T  Adeno T  No.  SV40 T  Adeno T 
examined  antigen  antigen  examined  antibody  antibody 
~denovirus 
W40 
Mixed 
~typical 
Total 
5 
0 
5 
1 
I1 
3  2  0 
5  2  0 
0  --  -- 
8  4  0 
5 
5 
1 
11 
3 
4 
0 
2 
5 
o 
ined)  and 7 of 13 sera analyzed contained antibody to adenovirus T  antigens. 
The  ratio  of adeno-like  tumors to  those  exhibiting  the  morphology of SV40 
tumors or those containing elements of both types is also similar to those pre- 
viously described with PARA-adenovirus 2  and PARA-adenovirus  7  tumors 
(7, 10). 
Tumors  induced  by  PARA-adenovirus  6  were  also  analyzed  (Table  IV). 
Surprisingly, none of the tumors in this series exhibited the fibroblastic SV40- 
like morphology.  Five of the  tumors were epithelioid-like adenovirus  tumors 
and  five contained  both  elements.  Only 4  of  8  tumors  contained  detectable RAPP,  JERKOFSKY,  MELNICK,  AND  LEVY  83 
levels of SV40 T  antigen with 7 of 11 sera containing the corresponding anti- 
body.  Seven sera also contained antibody against adenovirus T  antigen,  but 
none of the  tumors examined had detectable quantities  of the corresponding 
T  antigen. Again, this is similar to previous results which have revealed that, 
in the adenovirus system, detection of the T  antibody is more sensitive than 
detection of T  antigen. 
None of the cells examined contained SV40 V or adenovirus V antigen. None 
TABLE V 
E.~e~t of  Virus Immunization on Production of Tumors in  Weanling Hamsters by 
SV40-Transformed Cells 
Immunizing  virus 
None 
SV40 
Adenovirus 1 
Adenovirus 5 
Adenovirus 6 
Adenovirus 7 
Adenovirus 14 
Adenovirus 21 
PARA-adenovirus 1 
PARA-adenovirus 5 
PARA-sdenovirus 6 
PARA-adenovirus 7 
PARA-adenovirus 14 
PARA-sdenovirus 21 
Plaque-forming units per 
immunization* 
PARAS  Adenovirus§ 
__  lO~.O 
_  106.4 
_  10 5.6 
--  104.~ 
_  105.6 
__  106.S 
__  104.2 
10  s.s  104.4 
104.3  10  5.o 
104.~  104.2 
104.s  104.o 
104.2  106.3 
104 .x  104.2 
No. animals 
with tumors/ 
No. animals 
challenged 
31/32 
4/32 
22/32 
23/31 
29/32 
27/32 
28/32 
23/32 
18/31 
4/32 
11/32 
8/28 
8/32 
O/32 
No. of cells in 
one TPDIeH 
<100 
100,000 
500 
390 
<100 
100 
100 
390 
1,500 
100,000 
15,000 
25,000 
31,000 
> 100,000 
* Three inoculations given at weekly intervals. 
Obtained by plaque assay in green monkey kidney cells coinfected with a helper adenovi- 
Ins. 
§ Obtained by plaque assay in human embryonic kidney cells. 
[[ Final readings taken 12 weeks after inoculation of the challenge cells. 
of  the  sera  from  tumor-bearing  hamsters  contained  antibodies  to  SV40  V 
antigen  nor  did  these  sera  contain  antibodies  capable  of neutralizing  SV40 
virus.  However, a  number of sera from animals bearing  tumors induced  by 
PARA-adenovirus types 1 or 6  contained neutralizing antibodies against the 
homologous,  but  not  heterologous,  adenovirus.  Development  of  these  anti- 
bodies was presumably stimulated by the original inoculum. 
Effect  of  Immunization  with  PARA-Adenoviruses  on  Transplantability  of 
Cells Transformed by SV40.--It had been previously shown that immunization 84  ADENOVIRUSES  WITH  DEFECTIVE  SV40  GENOME 
of weanling hamsters with PARA-adenovims 7 (6) or with PARA-adenovirus 
2 (26) confers protection to hamsters against challenge with cells transformed 
by SV40. It was postulated that failure to enhance oncogenic potential of the 
adenoviruses in the weakly oncogenic group by the addition of PARA (Table 
I)  might be  due to the inability of these viruses  to enter the hamster cells 
efficiently to effect transformation. Such  failure  should also  be  reflected  by 
decreased protection against the SV40-transformed cells after immunization of 
the hamsters with the same viruses. 
To test this hypothesis,  groups of weanling hamsters were inoculated with 
PARA-adenoviruses  or with the parent PARA-free serotypes. The immunized 
animals were challenged  1 wk after the final  (3rd)  inoculation  with  10-fold 
increments  of H-50  cells. The immunizing dose  and the number of cells per 
one TPDs0 for each group at the termination of the experiment  12 wk post- 
challenge are shown in Table V. 
The H-50 cells were highly oncogenlc. Without prior immunization, tumors 
developed in 31 of 32 hamsters with less than 100 cells required for one TPDs0. 
Vaccination  of hamsters with SV40 protected them against cells transformed 
by the homologous virus and  100,000 cells were therefore  necessary  for one 
TPDs0. 
None of the parent PARA-free  adenovirus  serotypes  tested (types 1, 5, 6, 
7, 14, and 21) were capable of protecting hamsters against the H-50 cells. The 
number of cells required for one TPDs0 ranged from less than 100 (for adeno- 
virus 6)  to 500 with adenovirus  1. However,  animals inoculated with various 
PARA serotypes were protected against challenge with cells transformed by 
SV40. The most effective immunizing  populations were PARA-adenovirus 5 
and PARA-adenovirus 21;  100,000 cells or more were required  for a  TPDs0 
after inoculation with these populations.  PARA-adenovirus types 6,  7,  and 
14 also protected the animals but to a lesser extent than SV40 or the other 
PARA populations tested. The results  with PARA-adenovirus 7 were very 
similar  to those previously reported from this laboratory (5)  and the results 
for PARA-adenovirus types 5 and 21 resemble those previously reported with 
PARA-adenovirus 2  (26). PARA-adenovirns 1 was  relatively ineffective  in 
this series in protecting the animals  against H-50  cells. The lower levels of 
protection obtained with PARA--adenovirus  1 and PARA-adenovirus 6 may 
reflect the somewhat lower titers of PARA being carried by those populations. 
It should be pointed out that the amount of adenovirus (as measured by ability 
to form plaques in HEK cells) was constant within various serotypes tested. 
The time of tumor development in hamsters immunized with PARA-adeno- 
viruses  or the parent serotypes  after challenge with H-50  cells is shown  in 
Figs.  1 and 2. The TPD60 values were calculated at 2 wk intervals.  The ob- 
served  TPD60 remained constant  (required  more  than  100,000 transformed 
cells) throughout the duration of the experiments for groups of hamsters vac- I~PP,  SERKOFSKY~ MELNICK~ AND LEVY  85 
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Fzo. 1.  Development of tumors (expressed  as the number of cells required for one TPDs0) 
following challenge of hamsters with cells transformed  by SV40  (H-50 cell line). Hamsters 
were previously immunized with previously nononcogenie adenovirus serotypes  (I, 5, or 6) 
or with  transcapsidant  populations of  these serotypes  carrying a  defective SV40  genome 
(PARA). Contro]s include nonimmunized animals and animals inoculated with SV40 virus. 
cinated with  SV40,  PARA-adenovims 5  (Fig.  1)  and  PARA-adenovirus  21 
(Fig.  2).  Protection  afforded by PARA-adenovirus  6  (Fig.  1)  and  PARA- 
adenoviruses 7 and 14 (Fig.  2) dropped between the 4th and 6th wk and then 
remained fairly constant. When the parent adenovirus serotypes were used as 85  ADENOVIRUSES WITH  DEFECTIVE  SV40 GENOME 
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Fro. 2.  Development of tumors (expressed as the number of cells required for one TPD,0) 
following challenge of hamsters with cells transformed by SV40  (H-50  cell line). Hamsters 
had been previously immunized with weakly oncogenic adenovirus serotypes (7, 14, or 21) or 
with transcapsidant populations of these serotypes carrying a defective SV40 genome (PARA). 
Curves for nonimmunized animals and for animals immunized with SV40 virus are redrawn 
from Fig. 1 for purposes of comparison. RAPP~ JERKOFSKY, MELNICK, AND  LEVY  87 
immunizing agents, tumors continued to form so that the TPDs0 values dropped 
sharply for the first 10 wk.  Previous experience with the H-50  cells had re- 
vealed that new tumors do not develop after 12 wk following challenge of the 
animals with these cells. It is therefore  apparent from these  results  that im- 
munization with PARA-adenoviruses  confers significant immunity to hamsters 
against challenge with H-50 cells, but that immunization with the PARA-free 
parent adenovirus serotypes does not; this immunity was obtained with adeno- 
viruses  carrying PARA that were oncogenic as well as with those that were 
not rendered  oncogenic by the additon of the defective  SV40 genome being 
carried by PARA. 
DISCUSSION 
The original demonstration by Huebner and his colleagues (1) that a human 
adenovirus type 7 was  capable  of inducing tumors in hamsters having the 
antigenic characteristics  of SV40-induced tumors led to detailed analyses of the 
adenovirus type 7 population carrying the SV40 information. It was soon found 
that this population was morphologically  and antigenically homogeneous  (4, 
5, 27, 28); that is, all of the nucleic acid of the virus population was encased 
in adenovirus capsids. However,  the population did consist of two genotypes, 
one composed of the adenovirus type 7 DNA and the other including defective 
SV40 (8, 9,  15). It was also observed  that the SV40 genome carried  by the 
virus population contained the markers for the induction of SV40 T  antigen 
(4, 5) as well as for SV40-specific transplantation antigens (6) and that acqui- 
sition of this defective information enabled human adenoviruses to replicate in 
simian cells (2, 3, 12, 15, 28). Transfer of the defective SV40 information from 
the parent adenovirus type 7 to heterologous adenovirus serotypes by a process 
termed transcapsidafion (8, 9) resulted in the acquisition  of oncogenic poten- 
tial when the SV40 information was carried by adenovirus  type 2 (7,  10,  11). 
It was therefore  anticipated that transfer of this information to other adeno- 
virus serotypes would result in a  similar acquisition  of oncogenic potential. 
This  study clearly reveals  that  such  is  not the case  and  that oncogenic 
potential is acquired only by certain adenoviruses carrying the defective SV40 
genome in PARA. Since, as also revealed in this study, all PARA populations 
tested appear  capable  of inducing transplantation immunity to  cells trans- 
formed by SV40, it would appear that failure to enter the hamster cell is not 
the reason  for lack of oncogenic potential. It is,  however,  possible  that the 
adenovirus-PARA populations  can  enter  cells of  the  weanling  hamster  to 
transform them so that subsequent challenge of the immunological|y compe- 
tent animal with SV40 transformed cells is aborted. The same virus populations 
may, however, be unable to enter hamster embryonic cells to effect transfor- 
mation of those cells. Preliminary studies carried  out to determine the latter 
have revealed  that most adenovirus populations adsorb  and penetrate very 88  ADENOVIRUSES  WITH DEFECTIVE  SV40 GF.NO~E 
poorly into hamster embryonic cells, but no clear-cut difference  has been ob- 
served between those populations that are oncogenic  and those that are not 
oncogenic following the acquisition of PARA. 
Freeman et al. (29) have recently reported that adenovirus type 2 can trans- 
form primary rat embryo cells. Based on this observation and on serologic cross- 
reactions  between various virus-induced  tumor  antigens,  Huebner  (personal 
communication) has suggested that adenovirus types 1, 2, 5, and 6 represent a 
subgroup of adenoviruses.  This subgroup has been characterized earlier by its 
hemagglutination pattern (22), by possession of DNA of high GC content (24), 
and by hybridization results between viral DNA and tumor mRNA (30). The 
acquisition  by  these  same  serotypes  of  oncogenic  potential  when  carrying 
PARA supports their being grouped together. Other adenoviruses will have to 
be  tested  to  determine  the  limits  of  this  grouping;  such  tests of oncogenic 
potential after the transfer of PARA to other adenovirus serotypes  are presently 
under way in our laboratory. However, the fact that the acquisition of PARA 
by some nononcogenic adenoviruses renders them oncogenic, while other weakly 
oncogenic adenoviruses belonging  to the subgroup with DNA of intermediate 
GC content are not rendered more oncogenic, is of fundamental importance, and 
the systems described in this study will require additional detailed investiga- 
tion. 
SUMMARY 
The acquisition of the defective SV40 genome by a variety of human adeno- 
virus serotypes by the process of transcapsidation has resulted in the addition 
of oncogenic  potential for newborn hamsters to the previously nononcogenic 
adenovirus types l, 2, 5, and 6. These serotypes have previously been grouped 
together by the high GC content of their DNA. 
Transcapsidation of the SV40 genome to weakly oncogenic adenovirus types 
3,  14, 16, and 21 has failed to increase  their oncogenic potential although the 
parent adenovirus type 7 carrying PARA is highly oncogenic. These serotypes 
belong to the group possessing  a DNA of intermediate GC content. 
All the PARA-adenovirus populations, even those that were nononcogenic, 
were able to induce SV40 transplantation  immunity and therefore carry the 
SV40  transplantation  marker  as  well  as  the  marker  for  synthesis  of  SV40 
tumor or T  antigen. 
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